Regarding tranexamic acid:

  1. Administration requires dose reduction in hepatic impairment – renally excreted 95% unchanged
  2. It can only be given intravenously – topically in dentistry
  3. It competes for lysine binding sites on plasmin and plasminogen, blocking their interaction with fibrin
  4. It inhibits the fibrinolytic activity of plasminogen-streptokinase complex